Garvan Institute's TenK10K Project Aims to
Map 50 Million Human Cells from 10,000 People
PLEASANTON, Calif., Aug. 5, 2024
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a
leader in single cell and spatial biology, announced today its
involvement in TenK10K, a large-scale, multi-year study led by the
Garvan Institute of Medical Research. The TenK10K project intends
to map 50 million human cells from 10,000 people to identify unique
genomic fingerprints of autoimmune diseases, heart diseases and
cancer. For this groundbreaking project, the Garvan Institute
selected Chromium GEM-X products to generate single cell data to
improve the accuracy of predicting disease risk and treatment
response.
"TenK10K has the potential to enable a significant step forward
in personalized medicine," said Professor Joseph Powell, leader of the TenK10K project,
Program Director for Translational Genomics at the Garvan Institute
of Medical Research, and Director of the UNSW Cellular Genomics
Futures Institute. "Through single cell sequencing, which analyzes
individual cells rather than an average of many cells, we can see
fingerprints that we've never been able to distinguish. We are
excited by translational opportunities that come from combining
these leading sequencing and single cell technologies with advanced
machine learning methods."
One of the largest projects of its kind, TenK10K aims to improve
how accurately disease-linked immune cell fingerprints can be
identified and develop:
- Commercial tests to identify the right therapy for
challenging autoimmune diseases including multiple sclerosis,
rheumatoid arthritis, lupus, type 1 diabetes, spondylitis,
inflammatory bowel disease and Crohn's disease
- Early trials of powerful new RNA therapies
- Potential early targets for treatments for cancers and long
COVID
- Tests to track the aftermath of heart attacks and identify risk
of sudden death
As part of this new study, the Garvan Institute will use
Chromium GEM-X products, the next generation of 10x Genomics'
leading single cell technology, delivering increased sensitivity,
throughput, data quality and sample recovery. GEM-X is uniquely
positioned for translational research, delivering class-leading
performance at larger scale and lower cost, even with more
challenging samples.
"Single cell analysis at a massive scale has the potential to
make a massive impact on how we understand, diagnose, treat and
ultimately cure disease. We are thrilled to see the Garvan
Institute help turn this potential into reality and use our new
Chromium GEM-X technology as part of their groundbreaking TenK10K
project," said Ben Hindson,
Co-Founder and Chief Scientific Officer at 10x Genomics. "Enabling
more researchers to harness the full power of high-performance
single cell analysis at larger scale and lower cost is what drives
our continued velocity of innovation."
TenK10K builds on the early success of the Garvan Institute's
OneK1K pioneering study. For a 2022 paper published in
Science, Powell and a team of researchers used single cell
sequencing technologies from 10x Genomics to analyze the genomic
profile of more than one million cells from 1,000 people. This
study led to a proof-of-principle clinical trial at 10 hospitals in
Sydney, Australia to help match
individual patients with the most effective treatment.
"The early results suggest we can predict a patient's response
to a therapy based on their genetic profile," Powell added.
For the TenK10K project, the Garvan Institute has partnered with
Illumina, which is providing supplies, equipment and specialist
research support to the Garvan Institute.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on LinkedIn or
X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s products, performance, configuration,
capabilities, usage and anticipated projects utilizing 10x Genomics
technologies. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. Other risks and uncertainties that could affect 10x
Genomics' financial and operating results and cause actual results
to differ materially from those suggested by the forward-looking
statements made in this press release include those discussed under
the captions "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and
elsewhere in the documents 10x Genomics files with the Securities
and Exchange Commission (the "SEC") from time to time. Although 10x
Genomics believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot provide any
assurance that these expectations will prove to be correct nor can
it guarantee that the future results, levels of activity,
performance, usage and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to 10x Genomics as of the date hereof, and
10x Genomics disclaims any obligation to update any forward-looking
statements provided to reflect any change in its expectations or
any change in events, conditions or circumstances on which any such
statement is based, except as required by law. These
forward-looking statements should not be relied upon as
representing 10x Genomics' views as of any date subsequent to the
date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-technology-supports-tenk10k-project-led-by-garvan-institute-of-medical-research-to-help-transform-the-treatment-of-complex-diseases-302214699.html
SOURCE 10x Genomics, Inc.